We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Against a backdrop of widespread scrutiny of drug prices, Pharmacyclics opted to scrap a plan to triple the price of its blood cancer drug, Imbruvica (ibrutinib). Read More
Fresenius claimed it discovered “blatant fraud at the very top level of Akorn’s executive team [and] stunning evidence of blatant and pervasive data integrity violations,” after it had agreed to acquire the company last year — leading to its decision to pull out of the planned $4.3 billion deal. Read More
Opioid sales in the United States increased more than eightfold between 1992 and 2015, according to a new analysis by the FDA that found no clear links between price and volume. Read More
Pay-for-delay deals between branded and generic drugmakers in the European Union continued to decline in 2016, according to the latest update from the European Commission. Read More
Osiris Therapeutics filed a lawsuit against MiMedx Group for alleged theft of its clients and pre-paid commissions to Osiris’ longtime distributor Stability Biologics. Read More
U.S. drugmakers could be impacted by the Trump administration’s proposed tariff on thousands of Chinese goods, which includes pharmaceutical products and ingredients used in drug manufacturing — including epinephrine, psychotherapeutic agents, antidepressants and lidocaine, among others. Read More
A federal appeals court delayed a Patent Trial and Appeals Board review of Allergan’s patents for its dry-eye drug Restasis until after a court hears oral arguments on jurisdictional issues. Read More
The prices of 20 top-selling branded drugs increased at 10 times the price of inflation from 2012 to 2017, according to a new report released by Sen. Claire McCaskill (D-Mo.). Read More